Relafen 750, the advanced compound of naproxen, presents an intriguing case from the biochemical pharmacy standpoint. This mode of action, mainly involving suppression of cyclooxygenase enzymes namely COX-1 and COX-2 – leads to the reduction in prostaglandin production. Considering the biochemical framework, the drug's effectiveness is strongly a